Bert Klebl News Today

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Credit: Hauke S. Hillen A newly developed compound starves cancer cells by attacking their "power plants" - the so-called mitochondria. The new compound prevents the genetic information within mitochondria from being read. Researchers from the Max Planck Institute for Biology of Ageing in Cologne, the Karolinska Institute in Stockholm and the University of Gothenburg report in their study that this compound could be used as a potential anti-tumour drug in the future; not only in mice but also i...

Researchers at Karolinska Institutet in Sweden report in the journal Nature that they have developed novel first-in-class inhibitors that compromise mitochondrial function in cancer cells. Treatment with the inhibitors stopped cancer cells from proliferating and reduced tumour growth in mice, without significantly affecting healthy cells. "We are excited to have shown that this novel principle for cancer treatment works in animal models and hopefully the inhibitors can now be developed further...